Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study
Objective: The upcoming introduction of mepolizumab represents a promising treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The present study aimed to evaluate the effectiveness of mepolizumab on sinonasal outcomes of comorbid CRSwNP and severe asthma in a real-life setting. The prim...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Journal of Personalized Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4426/12/8/1304 |
| _version_ | 1797409384997847040 |
|---|---|
| author | Stefania Gallo Paolo Castelnuovo Luca Spirito Marta Feduzi Veronica Seccia Dina Visca Antonio Spanevello Erica Statuti Manuela Latorre Claudio Montuori Angela Rizzi Cristina Boccabella Matteo Bonini Eugenio De Corso |
| author_facet | Stefania Gallo Paolo Castelnuovo Luca Spirito Marta Feduzi Veronica Seccia Dina Visca Antonio Spanevello Erica Statuti Manuela Latorre Claudio Montuori Angela Rizzi Cristina Boccabella Matteo Bonini Eugenio De Corso |
| author_sort | Stefania Gallo |
| collection | DOAJ |
| description | Objective: The upcoming introduction of mepolizumab represents a promising treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The present study aimed to evaluate the effectiveness of mepolizumab on sinonasal outcomes of comorbid CRSwNP and severe asthma in a real-life setting. The primary endpoint was to evaluate changes in the SinoNasal Outcome Test (SNOT)-22 score, Nasal Polyp (NP) score, and blood eosinophil count during a 12-month treatment with mepolizumab. Secondary endpoints were to quantify mepolizumab’s effects on the mentioned parameters, identify clinical variables influencing the degree of response to treatment, and portray responder and nonresponder patients. Methods: A multicentric retrospective no-profit observational study on severe asthmatic patients, treated with mepolizumab, and comorbid CRSwNP was conducted. All patients were followed for at least 12 months. SNOT-22 score, NP score, and blood eosinophil count (and other CRS-specific variables) were collected at baseline and after 12 months. Results: Forty-three patients were included. A statistically significant reduction was observed for SNOT-22 score (mean t0 SNOT-22 54.8 ± 25.9; mean t12 SNOT-22 31.5 ± 21.3, <i>p</i> < 0.0001), NP score (median t0 NPS 3 (IQR 3); median t12 NPS 2 (IQR 4), <i>p</i> < 0.0001), and blood eosinophil count (mean t0 blood eosinophils 804.7 ± 461.5 cell/µL; mean t12 blood eosinophils 107.5 ± 104.6 cell/µL, <i>p</i> < 0.0001) after 12 months of treatment. Twenty patients (47%) gained improvement both in clinical and endoscopic outcome. Mepolizumab responder patients presented a t0 SNOT-22 significantly higher than nonresponders (<i>p</i> = 0.0011). Conclusions: Mepolizumab improved CRSwNP outcomes in a population of severe asthmatic patients. No clinical feature emerged to outline the profile of a “typical” responder patient, except for baseline SNOT-22 score, which seemed to affect the response to treatment. Further studies would be necessary to supplement these preliminary evaluations. |
| first_indexed | 2024-03-09T04:13:50Z |
| format | Article |
| id | doaj.art-300680ff694941eb9c8ed32ffbe1d820 |
| institution | Directory Open Access Journal |
| issn | 2075-4426 |
| language | English |
| last_indexed | 2024-03-09T04:13:50Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Personalized Medicine |
| spelling | doaj.art-300680ff694941eb9c8ed32ffbe1d8202023-12-03T13:56:18ZengMDPI AGJournal of Personalized Medicine2075-44262022-08-01128130410.3390/jpm12081304Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life StudyStefania Gallo0Paolo Castelnuovo1Luca Spirito2Marta Feduzi3Veronica Seccia4Dina Visca5Antonio Spanevello6Erica Statuti7Manuela Latorre8Claudio Montuori9Angela Rizzi10Cristina Boccabella11Matteo Bonini12Eugenio De Corso13Department of Otorhinolaryngology, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, 21100 Varese, ItalyDepartment of Otorhinolaryngology, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, 21100 Varese, ItalyDepartment of Otorhinolaryngology, Ospedale di Circolo e Fondazione Macchi, ASST Sette Laghi, 21100 Varese, ItalyUPLOAD (Upper and Lower Airways Inflammatory Diseases) Research Center, University of Insubria, 21100 Varese, ItalyOtolaryngology Audiology and Phoniatric Operative Unit, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, 56124 Pisa, ItalyUPLOAD (Upper and Lower Airways Inflammatory Diseases) Research Center, University of Insubria, 21100 Varese, ItalyUPLOAD (Upper and Lower Airways Inflammatory Diseases) Research Center, University of Insubria, 21100 Varese, ItalyOtolaryngology Audiology and Phoniatric Operative Unit, Department of Surgical, Medical, Molecular Pathology and Critical Care Medicine, Azienda Ospedaliero Universitaria Pisana, University of Pisa, 56124 Pisa, ItalyDepartment of Medical Specialties, Pulmonary Unit, Hospital of Massa, 54100 Massa, ItalyDepartment of Head and Neck and Sensory Organs, Catholic University of the Sacred Heart, 00168 Rome, ItalyUnit of Allergology, A. Gemelli Hospital Foundation IRCCS, 00168 Rome, ItalyDepartment of Internal Medicine and Geriatrics, Catholic University of the Sacred Hearth, 00168 Rome, ItalyDepartment of Internal Medicine and Geriatrics, Catholic University of the Sacred Hearth, 00168 Rome, ItalyDepartment of Head and Neck and Sensory Organs, Catholic University of the Sacred Heart, 00168 Rome, ItalyObjective: The upcoming introduction of mepolizumab represents a promising treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). The present study aimed to evaluate the effectiveness of mepolizumab on sinonasal outcomes of comorbid CRSwNP and severe asthma in a real-life setting. The primary endpoint was to evaluate changes in the SinoNasal Outcome Test (SNOT)-22 score, Nasal Polyp (NP) score, and blood eosinophil count during a 12-month treatment with mepolizumab. Secondary endpoints were to quantify mepolizumab’s effects on the mentioned parameters, identify clinical variables influencing the degree of response to treatment, and portray responder and nonresponder patients. Methods: A multicentric retrospective no-profit observational study on severe asthmatic patients, treated with mepolizumab, and comorbid CRSwNP was conducted. All patients were followed for at least 12 months. SNOT-22 score, NP score, and blood eosinophil count (and other CRS-specific variables) were collected at baseline and after 12 months. Results: Forty-three patients were included. A statistically significant reduction was observed for SNOT-22 score (mean t0 SNOT-22 54.8 ± 25.9; mean t12 SNOT-22 31.5 ± 21.3, <i>p</i> < 0.0001), NP score (median t0 NPS 3 (IQR 3); median t12 NPS 2 (IQR 4), <i>p</i> < 0.0001), and blood eosinophil count (mean t0 blood eosinophils 804.7 ± 461.5 cell/µL; mean t12 blood eosinophils 107.5 ± 104.6 cell/µL, <i>p</i> < 0.0001) after 12 months of treatment. Twenty patients (47%) gained improvement both in clinical and endoscopic outcome. Mepolizumab responder patients presented a t0 SNOT-22 significantly higher than nonresponders (<i>p</i> = 0.0011). Conclusions: Mepolizumab improved CRSwNP outcomes in a population of severe asthmatic patients. No clinical feature emerged to outline the profile of a “typical” responder patient, except for baseline SNOT-22 score, which seemed to affect the response to treatment. Further studies would be necessary to supplement these preliminary evaluations.https://www.mdpi.com/2075-4426/12/8/1304chronic rhinosinusitisnasal polypssevere asthmamepolizumabSNOT-22nasal polyp score |
| spellingShingle | Stefania Gallo Paolo Castelnuovo Luca Spirito Marta Feduzi Veronica Seccia Dina Visca Antonio Spanevello Erica Statuti Manuela Latorre Claudio Montuori Angela Rizzi Cristina Boccabella Matteo Bonini Eugenio De Corso Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study Journal of Personalized Medicine chronic rhinosinusitis nasal polyps severe asthma mepolizumab SNOT-22 nasal polyp score |
| title | Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study |
| title_full | Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study |
| title_fullStr | Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study |
| title_full_unstemmed | Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study |
| title_short | Mepolizumab Improves Outcomes of Chronic Rhinosinusitis with Nasal Polyps in Severe Asthmatic Patients: A Multicentric Real-Life Study |
| title_sort | mepolizumab improves outcomes of chronic rhinosinusitis with nasal polyps in severe asthmatic patients a multicentric real life study |
| topic | chronic rhinosinusitis nasal polyps severe asthma mepolizumab SNOT-22 nasal polyp score |
| url | https://www.mdpi.com/2075-4426/12/8/1304 |
| work_keys_str_mv | AT stefaniagallo mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT paolocastelnuovo mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT lucaspirito mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT martafeduzi mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT veronicaseccia mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT dinavisca mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT antoniospanevello mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT ericastatuti mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT manuelalatorre mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT claudiomontuori mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT angelarizzi mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT cristinaboccabella mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT matteobonini mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy AT eugeniodecorso mepolizumabimprovesoutcomesofchronicrhinosinusitiswithnasalpolypsinsevereasthmaticpatientsamulticentricreallifestudy |